Ivabradine (CAD) — Discount Pricing

Other medications in Heart & Cardiovascular

• Labetalol
• Lisinopril
• Losartan
• Lovastatin
• Macitentan
• Metolazone
• Metoprolol
• Metoprolol Succinate

About Ivabradine (CAD)

Ivabradine, commonly known by its brand name Corlanor, is an important medication for individuals managing chronic heart failure. It helps regulate heart rate, offering a path to improved quality of life. At TheDrugClub, we understand the financial burden of essential prescriptions. Discover how your membership can unlock significant savings on ivabradine, making vital heart care more accessible.

Living with chronic heart failure can be challenging, and managing your medication is a crucial part of maintaining your health. Ivabradine (brand name Corlanor) is a specific type of medication prescribed to help individuals with certain forms of heart failure and stable symptomatic angina.

What Ivabradine Treats

Ivabradine is primarily used to treat adults with chronic heart failure who have a reduced ejection fraction (HFrEF) and are in sinus rhythm with a resting heart rate of at least 70 beats per minute. It's often prescribed for patients who cannot tolerate or are not adequately controlled by beta-blockers. By specifically targeting the heart rate, ivabradine can help improve symptoms, reduce hospitalizations, and enhance overall quality of life for these patients. In some cases, it may also be used for symptomatic stable angina when other treatments aren't suitable or effective.

How Ivabradine Works

Unlike beta-blockers, ivabradine works by selectively inhibiting the *I(f)* (funny) current in the heart's sinoatrial node. This unique mechanism slows the heart rate without affecting the force of the heart's contractions or blood pressure significantly. By reducing the heart rate, ivabradine decreases the heart's workload and oxygen demand, which can alleviate symptoms of heart failure and angina. It's a targeted approach that offers a different pathway to

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ivabradine (CAD) is approved for (FDA label)

Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ivabradine (CAD) (FDA label)

Ivabradine tablets 5 mg: orange colored, capsule shaped, film-coated tablets, functionally scored with debossing "M" & "I" on one side and "2" on other side. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose. 7.5 mg: orange colored, round shaped, film-coated tablets debossed with “MI” on one side and “1” on the other side. Tablets: 5 mg, 7.5 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ivabradine (CAD) (FDA label)

Clinically significant adverse reactions that appear in other sections of the labeling include: • Atrial Fibrillation [ see Warnings and Precautions (5.2) ] • Bradycardia and Conduction Disturbances [ see Warnings and Precautions (5.3) ] Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals, LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ivabradine (CAD) (FDA label)

Ivabradine is contraindicated in patients with: • Acute decompensated heart failure • Clinically significant hypotension • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present • Clinically significant bradycardia [ see Warnings and Precautions (5.3) ] • Severe hepatic impairment [ see Use in Specific Populations (8.6) ] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [ see Drug Interactions (7.3) ] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [ see Drug Interactions (7.1) ] • Acute decompensated heart failure ( 4 ) • Clinically significant hypotension ( 4 ) • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present ( 4 ) • Clinically significant bradycardia ( 4 ) • Severe hepatic impairment ( 4 ) • Heart rate maintained exclusively by the pacemaker ( 4 ) • In combination with strong cytochrome CYP3A4 inhibitors ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.